Inhibitor Therapeutics Announces Major Clinical, Formulation, and IP Milestones on Itraconazole Program for Gorlin Syndrome

Key Highlights for Investors

• Near-term pharmacokinetic (PK) milestones outlined, with top-line results expected in Q2 2026
• Company highlights proprietary amorphous formulation strategy to address key limitations of itraconazole
• Global patent filing planned for the novel formulation, with potential to significantly strengthen the company’s IP position
• Indication targeted: Surgically eligible basal cell carcinomas (BCCs) in Gorlin Syndrome (BCCNS)

Summary of the Update

Inhibitor Therapeutics, Inc. (OTCQB: INTI) has released a comprehensive update on the progress of its itraconazole program for the treatment of surgically eligible basal cell carcinomas (BCCs) in patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS), also known as Gorlin Syndrome. This update encompasses clinical development, formulation innovation, and a new intellectual property (IP) strategy.

Clinical Program Progress

• The company is currently conducting a comparative PK, safety, and tolerability study in healthy adult subjects under fasting conditions in Malaysia. The study is a three-way crossover design against a reference listed drug and is being performed in collaboration with Avior Bio, Inc.
• The clinical program is proceeding according to the planned timelines and budget, supporting Inhibitor’s regulatory strategy under the FDA’s 505(b)(2) pathway.
• Key upcoming milestones:
  • Period 2 dosing scheduled for April 10, 2026
  • Period 3 dosing scheduled for April 24, 2026
  • Final PK sampling and bioanalysis to commence around May 1, 2026
  • Bioanalytical work expected to take two weeks, with an additional two weeks for statistical analysis
  • Top-line PK and relative bioavailability results are expected before the full Clinical Study Report
• The company believes this PK study is likely the final clinical study required before submission of a New Drug Application (NDA) to the FDA for its BCCNS program.

Formulation Innovation: Amorphous Itraconazole

• A major differentiator for Inhibitor Therapeutics is its proprietary amorphous formulation of itraconazole. Conventional crystalline itraconazole suffers from significant solubility issues, leading to variable absorption and systemic exposure.
• The company’s amorphous formulation strategy is designed to enhance solubility and dissolution by reducing particle agglomeration and improving dispersion, with the objective of supporting better intestinal absorption and more consistent pharmacokinetic profiles.
• Their Investigational Medicinal Product Dossier (IMPD) demonstrates that the formulated product is amorphous, as confirmed by X-ray diffraction, and was developed to suppress crystallization, directly addressing the known limitations of the crystalline form.

Intellectual Property: Planned Global Patent Filing

• Inhibitor is preparing a new patent application directed to the composition of its proprietary itraconazole formulation, with plans to seek global patent protection.
• If granted, the patent would be wholly owned by Inhibitor Therapeutics, without ongoing royalty obligations.
• This filing has the potential to materially strengthen the company’s IP portfolio, expanding protection around the formulation itself and complementing existing oncology-related itraconazole patents.
• The company believes that securing this patent could enhance the strategic value of the BCCNS program as it approaches NDA submission, commercialization, and potential partnership discussions.

Program Background & Market Implications

• Gorlin Syndrome (BCCNS) is a rare hereditary disorder characterized by the development of multiple BCCs throughout a patient’s life, often requiring repeated surgical interventions which carry significant morbidity.
• Inhibitor’s approach aims to provide a differentiated, non-surgical treatment option for these patients, addressing a significant unmet medical need.
• The company’s strategy of repurposing an already approved pharmaceutical ingredient, with patent-protected formulation, may accelerate time to market and reduce development risks relative to new chemical entities.

Potential Share Price Catalysts & Investor Takeaways

• Receipt of top-line PK and bioavailability data in Q2 2026 could be a significant catalyst for the stock, confirming the effectiveness of the amorphous formulation and supporting the NDA filing timeline.
• Grant of the new global formulation patent could materially increase the value of the company’s intellectual property estate, potentially enhancing the attractiveness of Inhibitor’s BCCNS program to partners and acquirers.
• As the company approaches completion of its final clinical study and NDA submission, investors should closely monitor updates regarding data readouts, regulatory interactions, and IP developments.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc. is a publicly traded, clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies using repurposed, patent-protected active pharmaceutical ingredients. The lead program is itraconazole for surgically eligible BCCs in BCCNS (Gorlin Syndrome). For more information, visit www.inhibitortx.com.

Investor Relations Contact

• Simon Bettink, VP of Operations
• Email: [email protected]

Disclaimer: This article is for informational purposes only and is not investment advice. It contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Investors should conduct their own due diligence before making any investment decision. The author and publisher accept no liability for any losses incurred as a result of reliance on this information.

View Inhibitor Therapeutics, Inc. Historical chart here